F. Valster

发表

Secondary Myelofibrosis in the Naturel History of JAK2, MPL and CALR Mutated Myeloproliferative Neoplasms

K. Schelfout, J. Michiels, F. Valster, 2015 .

2014 WHO Clinical Molecular and Pathological (WHO-CMP) Diagnostic Criteria for the Classification and Staging of Five Distinct JAK2, MPL and CALR Mutated Myeloproliferative Neoplasms

K. Schelfout, J. Michiels, F. Valster, 2014 .

Myelofibrosis is a Secondary Event in JAK2 Trilinear Myeloproliferative Neoplasm (MPN) and in CALR and MPL Thrombocythemia: Implications for Novel Treatment Options of Prefibrotic MPN

K. Schelfout, Z. Berneman, A. Gadisseur, 2017 .

Prospective Evaluation of WHO and European Clinical, Molecular and Pathological (WHO-ECMP) Criteria for Myeloproliferative Neoplasms (MPN) of Various Molecular Etiology: Characteristics of JAK2V617F, MPL515 and CALR Mutated MPN

K. Schelfout, T. Devos, F. Valster, 2015 .

Increased Erythrocyte Count on Top of Bone Marrow Histology but not Serum EPO Level or JAK2 Mutation Load Discriminates between JAK2V617F Mutated Essential Thrombocythemia and Polycythemia Vera

K. Schelfout, M. Medinger, J. Michiels, 2015 .

Severe thrombocytopenia in a pregnant patient with platelet-associated IgM, and known von Willebrand's disease; a case report.

F. Valster, J. Hutten, H. Feijen, 1990, European journal of obstetrics, gynecology, and reproductive biology.

Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

B. van der Holt, R. van der Griend, E. V. van Pampus, 2015, Haematologica.

Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.

J. Verweij, H. V. van Doorn, D. ten Bokkel Huinink, 2014, European journal of cancer.

European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms

K. Schelfout, J. Michiels, F. Valster, 2015 .

Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.

F. van Coevorden, K. Sikorska, J. V. van Sandick, 2018, The Lancet. Oncology.